-
公开(公告)号：US08507465B2
公开(公告)日：2013-08-13
申请号：US12739880
申请日：2008-10-24
IPC分类号： A61K31/56
CPC分类号： A61K31/495 , A61K31/56 , A61K31/57 , A61K2300/00
摘要： The present invention relates to a method of reducing the incidence of nausea and vomiting associated with the administration of oral contraceptive formulation and a method of preparation of oral contraceptive formulation comprising progestin and/or estrogen and an antiemetic. The preferred oral contraceptive formulation comprises of levonorgestrel and an antiemetic.
摘要翻译： 本发明涉及减少与口服避孕药物的给药相关的恶心和呕吐的发生率的方法以及包含孕激素和/或雌激素和止吐药的口服避孕药物的制备方法。 优选的口服避孕药制剂包含左炔诺孕酮和止吐剂。
-
公开(公告)号：US09211258B2
公开(公告)日：2015-12-15
申请号：US13583769
申请日：2011-03-09
IPC分类号： A61K31/44 , A61K9/10 , A61K31/428
CPC分类号： A61K31/437 , A23L27/00 , A23V2002/00 , A61K9/10 , A61K31/428
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
摘要翻译： 包含分散在悬浮液中的利福昔明和一种或多种药学上可接受的添加剂的稳定的，掩味的即用型悬浮液。 还提供了制备利福昔明的稳定的，掩味的即用型悬浮液的方法，包括以下步骤：将利福昔明与悬浮液基体混合，并通过研磨悬浮液进一步调节利福昔明颗粒，获得均匀分散的利福昔明悬浮液 。
-
公开(公告)号：US20090028940A1
公开(公告)日：2009-01-29
申请号：US12144453
申请日：2008-06-23
IPC分类号： A61K9/22 , A61K31/439 , A61P1/12 , A61K9/20 , A61K9/00
CPC分类号： A61K31/44 , A61K9/1623 , A61K9/1652 , A61K9/2086 , A61K9/2846 , A61K9/2866 , A61K9/4808 , Y02A50/473 , Y02A50/475
摘要： A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.
摘要翻译： 一种药物组合物，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或其多晶型物，药学上可接受的赋形剂和释放控制剂。 利福昔明的药物组合物包括：至少两个实体，其中一个实体是立即释放或快速释放，另一个实体是控制释放的。 多层片剂形式的药物组合物，包含至少一层，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映体或其多晶型物，药学上可接受的赋形剂; 所述层提供受控释放的利福昔明; 以及提供剂型在胃肠道中的延长停留时间的至少一个层。 包含具有体外溶出曲线的利福昔明的药物制剂，其中约70％的利福昔明在约24小时内释放。 所述组合物包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或多晶型物，一种或多种释放控制剂和引起致病根除的药学上可接受的赋形剂。
-
公开(公告)号：US08974825B2
公开(公告)日：2015-03-10
申请号：US12144894
申请日：2008-06-24
CPC分类号： A61K47/44 , A61K9/0065 , A61K9/0095 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K31/196 , A61K31/197 , A61K31/437 , A61K31/4402 , A61K31/606 , A61K31/635 , A61K31/655 , A61K31/785 , A61K38/12 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.
摘要翻译： 一种新型药物组合物，其包含治疗有效量的活性原理或其药学上可接受的盐或对映体或多晶型物，任选的一种或多种释放控制剂及其药学上可接受的赋形剂，其中所述组合物 配制成增加所述药物组合物和/或活性成分在胃肠道中的停留时间。 一种新型药物组合物，其包含至少两个实体，其中一个实体是即时释放/快速释放，另一个实体是控制释放的。 包含至少两个实体的药物组合物，其中一个实体是立即释放/快速释放，另一个实体是生物粘附的。 一种药物组合物，其包含：至少两个实体，其中一个实体被控制释放，另一个实体是生物粘附剂。所有三种组合物被配制以增加活性成分在胃肠道中的停留时间。 在层中具有活性的多层组合物，其提供活性成分和层的即时释放或控制释放，从而在GI道中提供增加的停留时间。
-
公开(公告)号：US20120214833A1
公开(公告)日：2012-08-23
申请号：US13503733
申请日：2010-10-27
IPC分类号： A61K31/437 , A61P31/00
CPC分类号： A61K31/437 , A61K9/0043 , A61K9/0046 , A61K9/0056 , A61K9/10 , A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K9/2086 , A61K47/10 , A61K47/32 , Y02A50/473
摘要： A solid dispersion of rifaximin comprising rifaximin and pharmaceutically acceptable carrier. A pharmaceutical composition comprising the solid dispersion of rifaximin.
摘要翻译： 利福昔明的固体分散体，其包含利福昔明和药学上可接受的载体。 包含利福昔明的固体分散体的药物组合物。
-
公开(公告)号：US20130072512A1
公开(公告)日：2013-03-21
申请号：US13583769
申请日：2011-03-09
IPC分类号： A61K31/437 , A61P31/04
CPC分类号： A61K31/437 , A23L27/00 , A23V2002/00 , A61K9/10 , A61K31/428
摘要： A stable, taste-masked, ready-to-use suspension comprising rifaximin dispersed in a suspension base and one or more pharmaceutically acceptable additive(s). Also provided is a process for preparing a stable, taste-masked, ready-to-use suspension of rifaximin comprising the steps of mixing rifaximin with the suspension base and further sizing the particles of rifaximin by milling the suspension to obtain a homogenously dispersed rifaximin suspension.
摘要翻译： 包含分散在悬浮液基中的利福昔明和一种或多种药学上可接受的添加剂的稳定的，掩味的即用型悬浮液。 还提供了制备利福昔明的稳定的，掩味的即用型悬浮液的方法，包括以下步骤：将利福昔明与悬浮液基体混合，并通过研磨悬浮液进一步调节利福昔明颗粒，获得均匀分散的利福昔明悬浮液 。
-
公开(公告)号：US08383151B2
公开(公告)日：2013-02-26
申请号：US12144453
申请日：2008-06-23
IPC分类号： A61K9/20
CPC分类号： A61K31/44 , A61K9/1623 , A61K9/1652 , A61K9/2086 , A61K9/2846 , A61K9/2866 , A61K9/4808 , Y02A50/473 , Y02A50/475
摘要： A pharmaceutical composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s) and release controlling agent(s). Pharmaceutical composition of rifaximin comprising: at least two entities wherein one entity is an immediate release or fast release and the other is controlled release. The pharmaceutical composition in the form of multilayer tablet comprising, at least one layer comprising, therapeutically effective amount of rifaximin or pharmaceutically acceptable salt or enantiomer or polymorph thereof, pharmaceutically acceptable excipient(s); said layer providing controlled release rifaximin; and at least one layer which provides increased residence time of the dosage form in the gastrointestinal tract. The pharmaceutical formulation comprising rifaximin having an in vitro dissolution profile, wherein about 70% of rifaximin is released in about 24 hours. The composition comprising therapeutically effective amount of rifaximin or pharmaceutically acceptable salt(s) or enantiomer(s) or polymorph(s) thereof, one or more release controlling agent(s) and pharmaceutically acceptable excipient(s) causing pathogenic eradication.
摘要翻译： 一种药物组合物，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或其多晶型物，药学上可接受的赋形剂和释放控制剂。 利福昔明的药物组合物包括：至少两个实体，其中一个实体是立即释放或快速释放，另一个实体是控制释放的。 多层片剂形式的药物组合物，包含至少一层，其包含治疗有效量的利福昔明或其药学上可接受的盐或对映体或其多晶型物，药学上可接受的赋形剂; 所述层提供受控释放的利福昔明; 以及提供剂型在胃肠道中的延长停留时间的至少一个层。 包含具有体外溶出曲线的利福昔明的药物制剂，其中约70％的利福昔明在约24小时内释放。 所述组合物包含治疗有效量的利福昔明或其药学上可接受的盐或对映异构体或多晶型物，一种或多种释放控制剂和引起致病根除的药学上可接受的赋形剂。
-
公开(公告)号：US20090011019A1
公开(公告)日：2009-01-08
申请号：US12144894
申请日：2008-06-24
CPC分类号： A61K47/44 , A61K9/0065 , A61K9/0095 , A61K9/1611 , A61K9/1617 , A61K9/1623 , A61K9/1635 , A61K9/1641 , A61K9/1652 , A61K9/2009 , A61K9/2013 , A61K9/2018 , A61K9/2027 , A61K9/2031 , A61K9/205 , A61K9/2054 , A61K9/2086 , A61K9/209 , A61K31/196 , A61K31/197 , A61K31/437 , A61K31/4402 , A61K31/606 , A61K31/635 , A61K31/655 , A61K31/785 , A61K38/12 , A61K47/32 , A61K47/34 , A61K47/38
摘要： A novel pharmaceutical composition, which comprises a therapeutically effective amount of active principle(s) or a pharmaceutically acceptable salt or enantiomer or polymorph thereof, optionally one or more release controlling agent(s) and pharmaceutical acceptable excipient(s) thereof, wherein the composition is formulated to increase the residence time of the said pharmaceutical composition and/or active principle(s) in the gastrointestinal tract. A novel pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is controlled release. A pharmaceutical composition comprising at least two entities wherein one entity is an immediate release/fast release and the other is bioadhesive. A pharmaceutical composition comprising: at least two entities wherein one entity is controlled release and the other is bioadhesive All the three compositions are formulated to increase the residence time of active principle(s) in the gastrointestinal tract. A multilayered composition with active in a layer which provides immediate release or controlled release of active principles and layer providing increased residence time in the GI tract.
摘要翻译： 一种新型药物组合物，其包含治疗有效量的活性成分或其药学上可接受的盐或对映体或多晶型物，任选的一种或多种释放控制剂及其药学上可接受的赋形剂，其中所述组合物 配制成增加所述药物组合物和/或活性成分在胃肠道中的停留时间。 一种新型药物组合物，其包含至少两个实体，其中一个实体是即时释放/快速释放，另一个实体是控制释放的。 包含至少两个实体的药物组合物，其中一个实体是立即释放/快速释放，另一个是生物粘附的。 一种药物组合物，其包含：至少两个实体，其中一个实体被控制释放，另一个实体是生物粘附剂。所有三种组合物被配制以增加活性成分在胃肠道中的停留时间。 在层中具有活性的多层组合物，其提供活性成分和层的即时释放或控制释放，从而在GI道中提供增加的停留时间。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.024 秒)
